Immunic (IMUX) said Thursday it closed its direct offering of about 5.67 million shares at $0.90 apiece, led by Aberdeen Investments.
Immunic said it plans to use the proceeds for clinical trials, operations and general corporate purposes. American Capital Partners division, Titan Partners Group, was the placement agent.
Price: 0.89, Change: -0.04, Percent Change: -4.27